Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan 7;54(1):4-12.
doi: 10.1093/jjco/hyad127.

Squamous cell carcinoma of the eyelid

Yasuyoshi Sato  1   2 , Shunji Takahashi  1 , Takashi Toshiyasu  3 , Hideki Tsuji  4 , Nobuhiro Hanai  5 , Akihiro Homma  6
Affiliations

Squamous cell carcinoma of the eyelid

Yasuyoshi Sato et al. Jpn J Clin Oncol. .

Abstract

Eyelid squamous cell carcinoma is a major type of rare eyelid cancer, together with basal cell carcinoma and sebaceous gland carcinoma. It is a painless disease that progresses slowly and is often detected by the appearance of nodules or plaques. Risk factors include exposure to ultraviolet light, fair skin, radiation and human papillomavirus infection. The standard treatment is surgical removal, and in cases of orbital invasion, orbital content removal is required. If sentinel node biopsy reveals a high risk of lymph node metastasis, adjuvant radiotherapy may be considered. Local chemotherapy, such as imiquimod and 5-fluorouracil, may be used for eyelid squamous cell carcinoma in situ. When surgery or radiotherapy is not recommended for distant metastases or locally advanced disease, drug therapy is often according to head and neck squamous cell carcinoma in Japan. The treatment often requires a multidisciplinary team to ensure the preservation of function and cosmetic appearance.

Keywords: SCC; cutaneous cancer; eyelid cancer; periocular cancer; squamous cell carcinoma.

PubMed Disclaimer

Conflict of interest statement

Yasuyoshi Sato reports personal fees from ONO Pharmaceutical Co, Ltd, Bristol-Myers Squibb Company, MSD K.K., Daiichi Sankyo Co, Ltd, Kaken Pharmaceutical Co, Ltd and Taiho Pharmaceutical Co, Ltd. Shunji Takahashi reports grants and personal fees from Bristol-Myers Squibb KK, ONO Pharmaceutical Co, Ltd, MSD, AstraZeneca, Chugai and BAYER, outside the submitted work.

References

    1. Maheshwari A, Finger PT. Cancers of the eye. Cancer Metastasis Rev 2018;37:677–90. - PubMed
    1. Obata H, Aoki Y, Kubota S, Kanai N, Tsuru T. Incidence of benign and malignant lesions of eyelid and conjunctival tumors. Nihon Ganka Gakkai Zasshi 2005;109:573–9. - PubMed
    1. Blumenthal SR, Swick M, Bayan CA, Ramanathan D, Maher I. Complex eyelid reconstruction: a practical guide for the Mohs surgeon. Dermatologic Surg 2022;48:916–23. - PubMed
    1. Kels BD, Grzybowski A, Grant-Kels JM. Human ocular anatomy. Clin Dermatol 2015;33:140–6. - PubMed
    1. Monheit G, Hrynewycz K. Mohs surgery for periocular tumors. Dermatol Surg 2019;45:S70–8. - PubMed

MeSH terms